Safety study of new experimental drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new experimental drug (called NCP-IL-22BP mRNA) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe, tolerable, and maybe effective against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have an advanced solid tumor (such as soft tissue sarcoma, head and neck cancer, or melanoma) that has not responded to standard treatments.
- You must be in reasonably good physical condition (able to take care of yourself and be up and about more than half the time).
- Your major organs (blood, liver, kidneys, heart) must be working well enough.
- You must have stopped other cancer treatments at least 28 days before starting (or 6 weeks for certain chemo drugs).
- You cannot be pregnant or breastfeeding, and you must agree to avoid pregnancy for 12 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a new drug that may help people with advanced solid tumors that have not responded to other treatments. The drug is given as an injection and aims to stop cancer growth.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This study tests an experimental drug (LNF1901) for people with advanced cancers that haven't responded to standard treatments. The goal is to see if it is safe and how well it works, and it might help control the cancer or shrink tumors.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.